The global CRO market is projected to hit almost $63 billion by the end of the decade, growing an average of 7.39% annually ...

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

British immunology firm Scancell has found a repeat buyer for its monoclonal antibodies.  | British immunology firm Scancell ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

Amsterdam-based health tech company myTomorrows is eyeing expansion into the Asia-Pacific region, opening an operations hub ...

Zimmer Biomet has scored an FDA clearance for a new component of its total knee replacement offering, aimed at patients who ...

Mitsubishi Tanabe Pharma is offering Dewpoint Therapeutics up to $480 million biobucks in a new research pact centering ...

While Applied Therapeutics has vowed to reapply or appeal the FDA’s recent rejection of its rare disease candidate govorestat ...

Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

GSK has terminated a phase 1/2 hepatitis B trial after the therapeutic vaccine regimen failed to meet the efficacy endpoint | GSK has terminated a phase 1/2 hepatitis B trial after the therapeutic ...

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...